Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
Clinical use of doxorubicin (Dox), an anthracycline with potent anti-tumor effects, is limited because of its highly chemotherapy-induced cardiotoxicity (CIC). After myocardial infarction (MI), we have recently identified Yin Yang-1 (YY1) and histone deacetylase 4 (HDAC4) as two factors involved in...
Main Authors: | Antonio Lax, Fernando Soler, Maria Josefa Fernandez del Palacio, Silvia Pascual-Oliver, Miriam Ruiz Ballester, Jose Javier Fuster, Domingo Pascual-Figal, Maria del Carmen Asensio-Lopez |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-06-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253123001178 |
Similar Items
-
Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01) -
Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01) -
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01) -
Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01) -
Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity
by: Tian-Hu Wang, et al.
Published: (2023-11-01)